Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Colorectal Neoplasms × RRx-001 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 3 Stomatitis 2 Small Cell Lung Carcinoma 2 Neoplasms 2 Mucositis 2 Mouth Neoplasms 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Carcinoma, Small Cell 2 Brain Neoplasms 2 Spinal Cord Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 165 Fluorouracil 130 Leucovorin 116 Cetuximab 108 Irinotecan 101 Oxaliplatin 92 pembrolizumab 89 Capecitabine 72 IFL protocol 46 Nivolumab 38 Folfox protocol 37 regorafenib 36 Panitumumab 36 Gemcitabine 27 Carboplatin 24 Cisplatin 23 trifluridine tipiracil drug combination 22 atezolizumab 20 Paclitaxel 19 Drug Therapy 18 Pemetrexed 17 130-nm albumin-bound paclitaxel 15 Ipilimumab 13 tislelizumab 11 spartalizumab 11 encorafenib 11 Trifluridine 11 Trastuzumab 11 HMPL-013 11 Cyclophosphamide 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02096354 2024-10-15

ROCKET

EpicentRx, Inc.

Phase 2 Completed

62 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡